ZDA
NVO

Zweig-DiMenna Associates’s Novo Nordisk NVO Stock Holding History

Zweig-DiMenna Associates’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-61,100
Closed -$8.72M – 94
2024
Q2 		$8.72M Buy
61,100
+9,100
+18% +$1.21M 0.98% 38
2024
Q1 		$6.68M Buy
+52,000
New +$6.19M 0.58% 62
2023
Q1 		– Sell
-178,000
Closed -$12M – 119
2022
Q4 		$12M Buy
+178,000
New +$10.4M 1.75% 16

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Zweig-DiMenna Associates's NVO Position: Q3 2024 in Review

Zweig-DiMenna Associates sold out of Novo Nordisk (NVO) in Q3 2024, closing a stake of 61,100 shares — an estimated $8.72M sold.

Zweig-DiMenna Associates first reported a position in NVO in Q4 2022 and held it in 3 quarters. The position peaked at $12M in Q4 2022. 1,784 funds tracked by Wall St. Rank hold NVO as of Q3 2024.

  • Zweig-DiMenna Associates reported no remaining Novo Nordisk position as of Q3 2024 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 61,100 Novo Nordisk shares in Q3 2024, an estimated $8.72M.
  • Zweig-DiMenna Associates first reported a position in Novo Nordisk in Q4 2022 and held it in 3 quarters.
  • Zweig-DiMenna Associates's Novo Nordisk position peaked at $12M in Q4 2022.
  • 1,784 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2024.

Based on Zweig-DiMenna Associates's 13F filing for Q3 2024, filed 23 Oct 2024.